Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech concluded the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, reflecting a solid liquidity position that supports ongoing research and development efforts. The company's diverse oncology pipeline, which includes mRNA-based drugs and various classes of immunotherapies, positions it favorably for potential therapeutic advancements and market expansions. Additionally, encouraging developments in the clinical evaluation of BNT323 and the improved immune responses demonstrated by their adapted COVID-19 vaccine enhance the company's outlook for sustained growth.

Bears say

The financial outlook for BioNTech is significantly challenged by various risks, including unfavorable data from multiple clinical programs and slower market adoption of their products. In the third quarter of 2025, the company reported a net loss per diluted share of €0.12, with a projected full-year loss of €3.99, indicating ongoing financial difficulties. Additionally, the changing dynamics in the COVID-19 vaccine market, particularly due to a more restrictive regulatory environment in the U.S., may detract investor focus from the company's oncology initiatives.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $140.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $140.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.